In this study, we demonstrate that locoregional administration of anti‐GPC3 CAR‐T cells via portal vein injection significantly enhances their efficacy in treating orthotopic HCC xenografts in mouse models, compared to the traditional systemic delivery via tail vein injection. Here, GPC3 is linked to hepatocellular carcinoma.